<DOC>
	<DOCNO>NCT03079297</DOCNO>
	<brief_summary>This randomized double-blind placebo-controlled crossover study seek evaluate antidepressant effect L-leucine , essential amino acid , patient Major Depressive Disorder ( MDD ) .</brief_summary>
	<brief_title>Rapid Antidepressant Effects Leucine</brief_title>
	<detailed_description>This pilot phase II clinical trial L-leucine test efficacy reduce depressive symptom MDD patient , especially exhibit increased inflammation . The determination increase inflammation do post-hoc . During screen visit , study participant provide demographic information complete self-report assessment clinician evaluation examination . Blood urine test also perform . All participant meet eligibility criterion willing proceed study enter 6-week study randomize two-week course either L-leucine placebo . In cross-over study , participant cross second treatment 2 week washout . The study period last 42 day ( 6 week ) baseline visit . Both L-leucine placebo provide effervescent mixture powder . Investigators hypothesize MDD subject great reduction depression severity leucine compare placebo .</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>Current primary diagnosis nonpsychotic major depressive disorder . Stable antidepressant dose one antidepressant medication 4 week anticipate change study period . Stable dos concomitant medication 6 week . No two fail antidepressant trial adequate dose duration , define ATRQ , current episode . Psychiatric comorbidity pose safety risk . Pregnant breastfeeding plan become pregnant ensue 2 month follow study entry sexually active use adequate contraception Exclusionary psychiatric condition ( substance dependence last 6 month , substance abuse last 2 month , lifetime history psychotic disorder . Unstable terminal general medical condition ( GMC ) . Concomitant medication interact Lleucine ( e.g . sildenafil ) . Vagus nerve stimulation , ECT , rTMS , somatic antidepressant treatment current episode Inadequately control hypothyroidism . Therapy depression specific , CBT Interpersonal Psychotherapy Depression . Hypersensitivity Lleucine Have Maple Syrup Urine Disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Antidepressant</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Biomarker</keyword>
	<keyword>Depression</keyword>
	<keyword>Treatment Resistant Depression</keyword>
	<keyword>Leucine</keyword>
</DOC>